The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Pharmaceutical giant Eli Lilly is finally weighing in on Hollywood’s obsession with Ozempic. In a commercial spot released Thursday, the company criticizes people who prescribe or take weight ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Eli Lilly's diverse portfolio shows broad growth, with significant contributions from oncology and other therapeutic areas.

Newly-launched obesity company Kailera Therapeutics has announced the appointment of Jamie Coleman as chief commercial ...

“If you have commercial drug insurance with coverage for Zepbound, you may be eligible to pay as low as $25 for a one- or three-month supply of Zepbound,” Eli Lilly says. “One month is ...

Global commercial executive with expertise across product lifecycle and therapeutic areas leading transformative brands, ...

Citi analyst Geoff Meacham lowered the firm’s price target on Eli Lilly to $1,190 from $1,250 and keeps a Buy rating on the shares. Ahead of ...

Weight loss treatments Mounjaro and Zepbound are the primary growth engines for Eli Lilly right now, but the company has another enormous opportunity that's getting very little attention.

Eli Lilly's stock price finished Jan. 16 down 21% from a peak it set last September. The sales trajectory of Mounjaro and Zepbound tapered off in the second half of 2024. An oral weight-loss candidate ...